Company intelligence / Profile preview

Advancium Health Network

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Advancium has acquired exclusive rights to evaluate the clinical-stage compound ALRN-6924 for retinoblastoma. Preclinical models have demonstrated on-mechanism antiproliferative activity in retinoblastoma cell lines, and prior clinical data exist for the compound in other indications but not yet for retinoblastoma specifically. No published clinical results from Advancium's direct studies yet.

Therapeutic areas: OncologyRare Diseases
Modalities: Small moleculePeptideMedical device
Industry: Biotech

Partnerships

Aileron Therapeutics (for ALRN-6924 program acquisition)Deerfield Management and Deerfield Foundation (funding/founding)Cure Innovation Labs (incubator for life science programs)

Beyond the preview

Go deeper on Advancium Health Network.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advancium Health Network.

Explore the full profile